Literature DB >> 22430380

Role of mesenchymal stem cell therapy in Crohn's disease.

Jignesh Dalal1, Kimberly Gandy, Jos Domen.   

Abstract

Many trials of mesenchymal stem cells (MSCs) have been published in the past 5-6 y. MSCs inhibit T-cell alloreactivity in vitro by soluble factors and direct cell-to-cell contact. They are safe to infuse in humans with no acute toxicity and no ectopic tissue formation. Promising results of MSC infusion for graft-vs.-host disease and fistulizing Crohn's disease (CD) have been published. Treatment of CD requires a comprehensive treatment approach to maintain symptomatic control, improve health-related quality-of-life measures, and minimize complications from the disease. In this review, we will discuss the results of clinical trials using a novel treatment in the form of MSCs for treatment of CD and related complications. Success of these phase I, II, and III trials have set the stage for usage of this novel treatment for children with CD.

Entities:  

Mesh：

Year:  2012        PMID： 22430380     DOI： 10.1038/pr.2011.56

Source DB:  PubMed          Journal:  Pediatr Res        ISSN： 0031-3998            Impact factor:   3.756


  38 in total

Review 1.  Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

Authors:  A Balan; G Lucchini; S Schmidt; A Schneider; L Tramsen; S Kuçi; R Meisel; P Bader; T Lehrnbecher
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

2.  Biological properties of extracellular vesicles and their physiological functions.

Authors:  María Yáñez-Mó; Pia R-M Siljander; Zoraida Andreu; Apolonija Bedina Zavec; Francesc E Borràs; Edit I Buzas; Krisztina Buzas; Enriqueta Casal; Francesco Cappello; Joana Carvalho; Eva Colás; Anabela Cordeiro-da Silva; Stefano Fais; Juan M Falcon-Perez; Irene M Ghobrial; Bernd Giebel; Mario Gimona; Michael Graner; Ihsan Gursel; Mayda Gursel; Niels H H Heegaard; An Hendrix; Peter Kierulf; Katsutoshi Kokubun; Maja Kosanovic; Veronika Kralj-Iglic; Eva-Maria Krämer-Albers; Saara Laitinen; Cecilia Lässer; Thomas Lener; Erzsébet Ligeti; Aija Linē; Georg Lipps; Alicia Llorente; Jan Lötvall; Mateja Manček-Keber; Antonio Marcilla; Maria Mittelbrunn; Irina Nazarenko; Esther N M Nolte-'t Hoen; Tuula A Nyman; Lorraine O'Driscoll; Mireia Olivan; Carla Oliveira; Éva Pállinger; Hernando A Del Portillo; Jaume Reventós; Marina Rigau; Eva Rohde; Marei Sammar; Francisco Sánchez-Madrid; N Santarém; Katharina Schallmoser; Marie Stampe Ostenfeld; Willem Stoorvogel; Roman Stukelj; Susanne G Van der Grein; M Helena Vasconcelos; Marca H M Wauben; Olivier De Wever
Journal:  J Extracell Vesicles       Date:  2015-05-14

Review 3.  Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications.

Authors:  Ying Wang; Xiaodong Chen; Wei Cao; Yufang Shi
Journal:  Nat Immunol       Date:  2014-11       Impact factor: 25.606

Review 4.  Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.

Authors:  Robert W Lindblad; Laarni Ibenana; John E Wagner; David H McKenna; Derek J Hei; Peiman Hematti; Larry A Couture; Leslie E Silberstein; Myriam Armant; Cliona M Rooney; Adrian P Gee; Lisbeth A Welniak; Traci Heath Mondoro; Deborah A Wood; David Styers
Journal:  Transfusion       Date:  2014-10-14       Impact factor: 3.157

Review 5.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor.

Authors:  Xianmei Meng; Rui-Jun Su; David J Baylink; Amanda Neises; Jason B Kiroyan; Wayne Yuk-Wai Lee; Kimberly J Payne; Daila S Gridley; Jun Wang; K-H William Lau; Gang Li; Xiao-Bing Zhang
Journal:  Cell Res       Date:  2013-03-12       Impact factor: 25.617

7.  Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via the 15d-PGJ2/PPARγ/TGF-β1 pathway.

Authors:  Jianxia Tang; Jimin Xiong; Tingting Wu; Zhangui Tang; Gang Ding; Chunmei Zhang; Songlin Wang; Yi Liu
Journal:  Stem Cells Dev       Date:  2014-07-01       Impact factor: 3.272

8.  Global hypoxia-ischemia induced inflammation and structural changes in the preterm ovine gut which were not ameliorated by mesenchymal stem cell treatment.

Authors:  Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs
Journal:  Mol Med       Date:  2016-04-14       Impact factor: 6.354

Review 9.  Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.

Authors:  Yur-Ren Kuo; Chien-Chang Chen; Shigeru Goto; Pao-Yuan Lin; Fu-Chan Wei; Chao-Long Chen
Journal:  Clin Dev Immunol       Date:  2012-11-25

10.  Therapeutic potential of mesenchymal stem cells in regenerative medicine.

Authors:  Devang M Patel; Jainy Shah; Anand S Srivastava
Journal:  Stem Cells Int       Date:  2013-03-19       Impact factor: 5.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.